Our pilot retrospective study26 in the University of Florida Health System found that CGM use in insulin-treated patients with diabetes and mild cognitive impairment or ADRD was associated with lower odds of all-cause mortality, while hypoglycemia-related hospitalizations were associated with increased the odds of mortality risk. The gene discussed is INS; the disease is Cognitive impairment.